新型冠状病毒奥密克戎变异株的研究进展：对其科学防控措施的启示

doi:10.19871/j.cnki.xfcrbzz.2022.01.001

摘要/Abstract

摘要： 新型冠状病毒肺炎的大流行仍然是全球公共卫生系统的巨大威胁。截至2022年1月11日16点52分,过去24h内全球新增1 738 701例感染病例和5150例死亡病例。最近,新型冠状病毒在全球范围内出现了多种变异株,特别是B.1.1.529变异株奥密克戎（Omicron）,该变异株在其刺突蛋白中含有大量的突变,这些突变的位置是先前感染或疫苗引发的多种免疫反应的靶点,正是这些突变导致了奥密克戎变异株对人体产生中和作用进而发生免疫逃逸。由奥密克戎变异株感染产生的疾病症状比之前的变异株更轻,轻型患者的比例升高和住院率降低。然而,由于奥密克戎变异株的超高传播率,在一些国家和地区,奥密克戎变异株感染病例数在数周内就已超过了德尔塔（Delta）和其他病毒变异株,全球卫生系统仍然面临着巨大的压力。本文概述了奥密克戎变异株的免疫逃逸、低致病性和高传染性特征的分子机制,并在此基础上针对奥密克戎变异株的防控提供了科学的建议。

关键词: 新型冠状病毒, 新型冠状病毒肺炎, 奥密克戎, 关切变异株, 刺突蛋白

Abstract: Coronavirus disease 2019 (COVID-19) pandemic is still a great threat to global public health, with a daily increase of 1 738 701 cases and 5150 deaths in 11 January, 2022. Recently, multiple variants of 2019-nCoV have emerged around the world, especially the newly 2019-nCoV variant B.1.1.529 (Omicron), a variant of concern (VOC), which are harboring up large number of mutations in its spike protein, the target of multi-faceted immune response generated by both prior infection or vaccination, leading to the immune evasion of neutralization. Optimistically, Omicron infection produces milder disease than previous strains, such as increased proportion of asymptomatic or mild cases and fewer hospital admissions. However, global health systems could still come under huge pressure considering the super spread rate of Omicron variant, which has outcompeted Delta and other variants within weeks in some countries and regions. Therefore, here we reviewed the molecular mechanism underlying the immune evasion, milder pathogenicity and enhanced transmissibility of Omicron, and further provided scientific suggestions to prevent and control the Omicron variant.

Key words: 2019 novel coronavirus, Coronavirus disease 2019, Omicron, Variant of concern, Spike protein

廖康生, 卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展：对其科学防控措施的启示[J]. 新发传染病电子杂志, 2022, 7(1): 1-5.

Liao Kangsheng, Lu Hongzhou. Current studies in 2019-nCoV Omicron variant: implications for scientific prevention and control strategies[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(1): 1-5.

参考文献

[1] WORLD HEALTH ORGANIZATION. Global influenza strategy2019-2030[EB/OL]. [2019-03-11].www.pharmaceutical-technology.com.
[2] WORLD HEALTH ORGANIZATION.Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern[EB/OL].[2021-11-28].https://www.who.int/news/item/26-11-2021.
[3] WORLD HEALTH ORGANIZATION.Enhancing Readiness for Omicron (B.1.1.529)[EB/OL].[2021-12-10].https://www.who.int/publications/m/item/enhancing.
[4] KUPFERSCHMIDT K.Where did ‘weird’Omicron come from? : American[R]. Association for the Advancement of Science, 2021.
[5] GARCIA-BELTRAN WF, LAM EC, DENIS KS, et al.Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity[J]. Cell, 2021,184(9): 2372-2383.
[6] SKUMS P, KIRPICH A, BAYKAL PI, et al.Global transmission network of SARS-CoV-2: From outbreak to pandemic[J]. MedRxiv, 2020:32511620.
[7] WORLD HEALTH ORGANIZATION. Tracking SARS-CoV-2 variants2021[EB/OL]. [2021-06-07]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[8] DEL RIO C, OMER SB, MALANI PN.Winter of Omicron—The Evolving COVID-19 Pandemic[J]. JAMA, 2021, 327(4):319-320.
[9] ZAHRADNÍK J, MARCIANO S, SHEMESH M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution[J]. Nat microbiol, 2021, 6(9): 1188-1198.
[10] CAMERONI E, SALIBA C, BOWEN JE, et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift[J]. Nature, 2022, 602(7898):664-670.
[11] MILLER NL, CLARK T, RAMAN R, et al.Insights on the mutational landscape of the SARS-CoV-2 Omicron variant[J]. bioRxiv, 2021:34931194.
[12] YIN W, XU Y, XU P, et al.Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody: mechanisms for the high infectivity, immune evasion and antibody drug discovery[J]. bioRxiv, 2021.
[13] HAN P, LI L, LIU S, et al.Receptor binding and complex structures of human ACE2 to spike RBD from Omicron and Delta SARS-CoV-2[J]. Cell, 2022, 185(4):630-640.
[14] HE X, HONG W, PAN X, et al.SARS-CoV-2 Omicron variant: characteristics and prevention[J]. MedComm, 2021, 2(4):838-845.
[15] UK PARLIAMENT.COVID-19: The Omicron Variant[EB/OL]. [2019-03-11].https://post.parliament.uk/covid-19-the-omicron-variant/.
[16] BROWN J, ZHOU J, PEACOCK TP, et al.The SARS-CoV-2 variant, Omicron, shows enhanced replication in human primary nasal epithelial cells[J]. bioRxiv, 2022.
[17] CHAN MC, HUI KP, HO J, et al.SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo[J]. mBio, 2021, 12(4): e0085021.
[18] MCMAHAN K, GIFFIN V, TOSTANOSKI L, et al.Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters[J]. bioRxiv, 2022.
[19] BENTLEY EG, KIRBY A, SHARMA P, et al.SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19[J]. bioRxiv, 2021.
[20] BOJKOVA D, WIDERA M, CIESEK S, et al.Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates[J]. Cell Res, 2022, 2022(1):1-3.
[21] PIERROS V, KONTOPODIS E, STRAVOPODIS DJ, et al.Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through Analysis of Spike Protein-specific Core Unique Peptides[J]. medRxiv, 2021.
[22] PULLIAM JR, VAN SCHALKWYK C, GOVENDER N, et al.Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa[J]. medRxiv, 2021.
[23] LU L, MOK BW-Y, CHEN L, et al.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients[J]. Clin Infect Dis, 2021, 16: 1039-1041.
[24] DEJNIRATTISAI W, HUO J, ZHOU D, et al.SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185(3):467-484.
[25] CAO YR, WANG J, JIAN F, et al.B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes[J]. BioRxiv, 2021.
[26] WILLETT BJ, GROVE J, MACLEAN O, et al.The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism[J]. medRxiv, 2022.
[27] 郝鹏飞, 许汪, 杜寿文, 等. 冠状病毒起源,受体及新型冠状病毒检测与疫苗最新研究进展[J/CD]. 新发传染病电子杂志,2020,5(2): 74-78.
[28] 李倩, 卢洪洲. 新型冠状病毒疫苗研究最新进展[J/CD]. 新发传染病电子杂志, 2020, 5(4): 274-276.
[29] GARCIA-BELTRAN WF, DENIS KJS, HOELZEMER A, et al.mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant[J]. Cell, 2021, 185(3):457-466.
[30] JACOBSEN H, STRENGERT M, MAASS H, et al.Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations[J]. medRxiv, 2021.
[31] ZHOU R, TO KK-W, PENG Q, et al.Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses[J]. Clin Transl Med, 2022, 12(1):e720.
[32] KEETON R, TINCHO MB, NGOMTI A, et al.SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron[J]. medRxiv, 2021, 127:102792.
[33] BAR-ON YM, GOLDBERG Y, MANDEL M, et al.Protection of BNT162b2 vaccine booster against Covid-19 in Israel[J]. N Engl J Med, 2021, 385(15): 1393-1400.
[34] ANDREWS N, STOWE J, KIRSEBOM F, et al.Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study[J]. MedRxiv, 2021.
[35] PILISHVILI T, GIERKE R, FLEMING-DUTRA KE, et al.Effectiveness of mRNA Covid-19 vaccine among US health care personnel[J]. N Engl J Med, 2021,385(25): e90.
[36] YANG L, LIU W, YU X, et al.COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19[J]. Antib Ther, 2020, 3(3): 205-212.
[37] VANBLARGAN LA, ERRICO JM, HALFMANN P, et al.An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies[J]. Nat Med, 2022, 19:1-6.
[38] KANNAN SR, SPRATT AN, SHARMA K, et al.Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies[J]. J Autoimmun, 2022, 126:102779.
[39] TOURET F, BARONTI C, BOUZIDI HS, et al.In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B. 1.1. 529 isolate[J]. bioRxiv, 2022.